Business, energy, technology, markets and global industry news from Business News Today

AK111

PharmaDeviceNews AK111
Representative image: A dermatologist discusses plaque psoriasis treatment with a patient, reflecting Akeso’s gumokimab approval and the intensifying IL-17 biologics race in China’s autoimmune disease market.
Pharma & Biotech

Why Akeso’s gumokimab approval could sharpen China’s psoriasis biologics race

Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and IL-17 competition.

Read More
Pharma & Biotech

Akeso’s gumokimab advances to NMPA review in ankylosing spondylitis: Is China’s IL-17 race entering a new phase?

Akeso’s gumokimab enters NMPA review for ankylosing spondylitis after Phase 3 success. Find out what this could mean for IL-17 therapies in China.

Read More